Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Accusing an entire organization like the FDA (U.S.

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153887
(Total Views: 583)
Posted On: 07/20/2023 6:53:43 PM
Posted By: ohm20
Re: biloxiblues #135884
Quote:
Accusing an entire organization like the FDA (U.S. Food and Drug Administration) of being corrupt is a serious allegation that should be supported by substantial evidence.



The whole of the FDA is not corrupt but some within the agency almost certainly are.

Quote:
What a congressional investigation reveals about FDA's approval of Aduhelm

In its investigation, the committees found that FDA's approval of Aduhelm was "rife with irregularities" and "raise serious concerns about [the agency's] lapses in protocol."

Between July 2019 and July 2020, FDA and Biogen created a "working group" to analyze Aduhelm's clinical trials, engaging in at least 115 meetings, calls, and email exchanges—interactions that the report called "atypical." The committees also found that at least 66 calls and email exchanges were not properly documented.

The report also highlighted concerns with Aduhelm's accelerated approval status, which it "abruptly" gained after "unfavorable feedback" from an advisory committee through the traditional approval process. Granting Aduhelm accelerated approval was also against FDA's guidance for Alzheimer's drugs, which stated the disease had not yet met "the standard for accelerated approval."

In addition, FDA initially recommended Aduhelm for all patients with Alzheimer's, despite the drug only being tested in patients with early-stage disease. In fact, Biogen's advisors warned against a broad label for the drug, saying that it could lead to safety risks and other issues. However, it was only after public pushback and confusion that Biogen asked for Aduhelm's label to be narrowed.
https://www.advisory.com/daily-briefing/2023/...estigation




(15)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us